Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: microRNA therapeutics - Regulus Therapeutics

Drug Profile

Research programme: microRNA therapeutics - Regulus Therapeutics

Alternative Names: anti-miR-10b; anti-miR-122; anti-miR-132; miR-122; miR-296; miR-34; miR-34a; miR-K12-11 (viral oncomir); miR-X; miRNA therapeutics - Regulus Therapeutics; RGLS 5579; RGLS 6650; Viral microRNAs - Regulus Therapeutics

Latest Information Update: 27 May 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator California Institute of Technology/CalTech; Stanford University
  • Developer Cenix BioScience; Regulus Therapeutics
  • Class Anti-infectives; Antihyperglycaemics; Antineoplastics; Antisense oligonucleotides; Antivirals; Cardiovascular therapies; Heart failure therapies; Hepatoprotectants; MicroRNAs
  • Mechanism of Action MicroRNA inhibitors; MicroRNA modulators; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Non-alcoholic steatohepatitis

Highest Development Phases

  • Preclinical Glioblastoma; Hepatitis B; Hepatitis C; Immunological disorders; Infections; Non-alcoholic steatohepatitis
  • Discontinued Diabetes mellitus; Heart failure; Metabolic syndrome; Viral infections

Most Recent Events

  • 24 May 2019 Preclinical trials in Hepatitis C in USA (unspecified route), before May 2019
  • 09 May 2019 Research programme: microRNA therapeutics - Regulus Therapeutics is available for licensing as of 09 May 2019. http://regulusrx.com/
  • 08 Apr 2019 Pharmacodynamics data from preclinical studies in Non-alcoholic steatohepatitis released by Regulus Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top